Coin Press - AstraZeneca buys US biotech firm CinCor

NYSE - LSE

RBGPF	100%	59.33	$
SCS	-1.33%	12.78	$
BCC	0.53%	142.02	$
RYCEF	-0.87%	6.91	$
AZN	0%	76.87	$
BTI	0.06%	35.22	$
CMSC	0.28%	24.64	$
NGG	0.64%	65.9	$
RIO	-4.44%	66.66	$
GSK	-1.6%	38.02	$
JRI	-0.15%	13.16	$
BCE	-0.06%	33.51	$
RELX	1.29%	46.64	$
CMSD	0.25%	24.851	$
BP	-3.47%	32.03	$
VOD	-0.31%	9.66	$

AstraZeneca buys US biotech firm CinCor / Photo: Jonathan NACKSTRAND - AFP/File

AstraZeneca buys US biotech firm CinCor

ECONOMY 09.01.2023

Anglo-Swedish pharmaceuticals giant AstraZeneca on Monday agreed to buy US biotech company CinCor for $1.8 billion, expanding further into the field of heart and kidney drugs.

Text size:

The takeover marks the latest push by Astra chief executive Pascal Soriot to bolster the Covid vaccine maker's pipeline of new products.

Massachusetts-based CinCor focuses on developing treatments for hypertension and chronic kidney disease.

Since taking the helm at AstraZeneca in 2012, Frenchman Soriot has expanded the company into lucrative cancer therapies.

The group completed a blockbuster takeover of Alexion for $39 billion in 2021, giving it more heft in areas such as treating blood disorders.

X.Wong--CPN

Coin Press - AstraZeneca buys US biotech firm CinCor

AstraZeneca buys US biotech firm CinCor

Featured

Braving war: Lebanon's 'badass' airline defies odds

US weighs Google breakup in landmark trial

Chinese stocks tumble on stimulus upset, Asia tracks Wall St higher

7-Eleven owner confirms new takeover offer from Couche-Tard